CPT® Code 84112

Evaluation of cervicovaginal fluid for specific amniotic fluid protein(s) (eg, placental alpha microglobulin-1 [PAMG-1], placental protein 12 [PP12], alpha-fetoprotein), qualitative, each specimen

The evaluation of cervicovaginal fluid for specific amniotic fluid proteins is a diagnostic procedure utilized primarily when there is a suspicion of premature rupture of membranes (PROM). This condition can lead to significant complications during pregnancy, making timely and accurate diagnosis crucial. The proteins assessed in this evaluation include placental alpha microglobulin-1 (PAMG-1), placental protein 12 (PP12), and alpha-fetoprotein (AFP). PAMG-1 is a protein that is produced in the fetal liver and yolk sac, and its concentration in amniotic fluid increases significantly during the second and third trimesters of pregnancy. PP12, on the other hand, is synthesized by the placental decidua and reaches its peak levels in the amniotic fluid during the first trimester, remaining elevated until delivery. AFP is another important protein that is initially produced by the yolk sac in early gestation and subsequently by the fetal liver and gastrointestinal tract. The testing process involves swabbing the cervix and vagina to collect cervicovaginal secretions, which are then analyzed using immunoassay techniques. These techniques employ a series of monoclonal and/or polyclonal antibodies to detect the presence of one or more of these specific proteins. The results of this evaluation can provide critical information regarding the integrity of the amniotic sac and help guide clinical decision-making in the management of the pregnancy.